EA201892057A1 - Соединения-коагонисты гип и гпп-1 - Google Patents
Соединения-коагонисты гип и гпп-1Info
- Publication number
- EA201892057A1 EA201892057A1 EA201892057A EA201892057A EA201892057A1 EA 201892057 A1 EA201892057 A1 EA 201892057A1 EA 201892057 A EA201892057 A EA 201892057A EA 201892057 A EA201892057 A EA 201892057A EA 201892057 A1 EA201892057 A1 EA 201892057A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- glp
- coagonists
- gui
- connections
- peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Настоящее изобретение относится к соединениям-двойным миметикам пептида инкретина, которые выступают в роли агонистов рецепторов глюкозозависимого инсулинотропного полипептида (ГИП) и глюкагоноподобного пептида-1 (ГПП-1) человека, и могут являться пригодными для лечения сахарного диабета 2 типа (СД2Т).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562101488P | 2015-01-09 | 2015-01-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201892057A1 true EA201892057A1 (ru) | 2019-02-28 |
EA035055B1 EA035055B1 (ru) | 2020-04-22 |
Family
ID=55315708
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090392A EA202090392A3 (ru) | 2015-01-09 | 2016-01-05 | Соединения-коагонисты гип и гпп-1 |
EA201892057A EA035055B1 (ru) | 2015-01-09 | 2016-01-05 | Соединения-коагонисты гип и гпп-1 |
EA201791281A EA031591B1 (ru) | 2015-01-09 | 2016-01-05 | Соединения-коагонисты гип и гпп-1 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090392A EA202090392A3 (ru) | 2015-01-09 | 2016-01-05 | Соединения-коагонисты гип и гпп-1 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201791281A EA031591B1 (ru) | 2015-01-09 | 2016-01-05 | Соединения-коагонисты гип и гпп-1 |
Country Status (45)
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4212180A1 (en) | 2013-12-18 | 2023-07-19 | The Scripps Research Institute | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
WO2018104263A1 (en) | 2016-12-06 | 2018-06-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
EP3624828A4 (en) * | 2017-05-18 | 2021-03-03 | Merck Sharp & Dohme Corp. | PHARMACEUTICAL FORMULATION WITH INCRETIN-INSULIN CONJUGATES |
TWI809515B (zh) * | 2017-12-21 | 2023-07-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
TWI767095B (zh) * | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
WO2019140030A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
PE20210473A1 (es) * | 2018-05-04 | 2021-03-08 | Novo Nordisk As | Derivados de gip y usos de estos |
TWI705820B (zh) * | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
CA3107344A1 (en) | 2018-07-23 | 2020-01-30 | Eli Lilly And Company | Methods of using a gip/glp1 co-agonist for therapy |
KR20210024081A (ko) * | 2018-07-23 | 2021-03-04 | 일라이 릴리 앤드 캄파니 | 당뇨병을 위한 gip/glp1 공효능제의 사용 방법 |
MX2021000793A (es) | 2018-07-23 | 2021-04-12 | Lilly Co Eli | Compuestos coagonistas de gip/glp1. |
JP6564539B1 (ja) | 2018-09-14 | 2019-08-21 | 長瀬産業株式会社 | スルホン酸化合物によるペプチド精製方法 |
EP3856339A1 (en) | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
TWI799680B (zh) | 2019-01-29 | 2023-04-21 | 美商美國禮來大藥廠 | 製備gip/glp1雙重促效劑之方法 |
KR20220020879A (ko) | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
TWI764209B (zh) * | 2019-08-01 | 2022-05-11 | 美商美國禮來大藥廠 | Gipr促效劑化合物 |
BR112022001081A2 (pt) | 2019-08-19 | 2022-05-24 | Lilly Co Eli | Métodos para produzir análogos de incretina |
JP2022551282A (ja) | 2019-10-04 | 2022-12-08 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、及びglp-1受容体及びgip受容体二重アゴニストを含む組成物及びその治療学的使用 |
CN110684082B (zh) * | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
AR120714A1 (es) * | 2019-12-18 | 2022-03-09 | Lilly Co Eli | Análogos de incretina y sus usos |
US20230265151A1 (en) * | 2020-01-23 | 2023-08-24 | Eli Lilly And Company | Gip/glp1 co-agonist compounds |
TW202140058A (zh) * | 2020-01-30 | 2021-11-01 | 美商美國禮來大藥廠 | 提派肽(tirzepatide)之治療用途 |
CN111253475B (zh) * | 2020-02-18 | 2021-03-09 | 江苏诺泰澳赛诺生物制药股份有限公司 | Glp-1激动多肽化合物及其盐与合成方法及用途 |
CA3174635A1 (en) | 2020-03-06 | 2021-09-10 | Sanofi | Peptides as selective gip receptor agonists |
CN113493503B (zh) * | 2020-04-08 | 2022-08-05 | 浙江道尔生物科技有限公司 | 一种肠促胰岛素类似物及其制备方法和用途 |
TW202216746A (zh) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型glp-1/gip雙重促效劑 |
TW202214679A (zh) | 2020-07-22 | 2022-04-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及gip受體共促效劑 |
IL299701A (en) | 2020-07-22 | 2023-03-01 | Novo Nordisk As | GLP-1 and GIP receptor co-agonists suitable for oral administration |
CN115925995A (zh) * | 2020-09-30 | 2023-04-07 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
IL301109A (en) | 2020-10-17 | 2023-05-01 | Sun Pharmaceutical Ind Ltd | Dual GLP-1/GIP agonists |
WO2022117056A1 (zh) * | 2020-12-02 | 2022-06-09 | 南京明德新药研发有限公司 | 含内酰胺修饰的多肽类化合物 |
CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
CA3208873A1 (en) * | 2021-02-17 | 2022-08-25 | Mathijs Christiaan Michael BUNCK | Gip/glp1 dual agonist therapeutic methods |
WO2022177742A2 (en) | 2021-02-17 | 2022-08-25 | Eli Lilly And Company | Tirzepatide therapeutic methods |
US20240150425A1 (en) * | 2021-03-25 | 2024-05-09 | Brightgene Bio-Medical Technology Co., Ltd. | Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use |
JP2024511107A (ja) | 2021-03-25 | 2024-03-12 | ブライトジーン バイオ-メディカル テクノロジー カンパニー リミテッド | Gipとglp-1の二重受容体作動薬、医薬組成物および使用 |
WO2022235991A1 (en) | 2021-05-07 | 2022-11-10 | Eli Lilly And Company | Erodible tablet |
TWI827077B (zh) * | 2021-05-28 | 2023-12-21 | 大陸商廣東眾生睿創生物科技有限公司 | 多肽的製備及其應用 |
EP4345105A1 (en) * | 2021-06-01 | 2024-04-03 | Nanjing Zhine Medicine Technology Co., Ltd. | Polypeptide derivative having effect of dual targeted activation of glp-1r and gipr, preparation method therefor, and use thereof |
WO2022262825A1 (zh) * | 2021-06-18 | 2022-12-22 | 南京明德新药研发有限公司 | 含内酰胺桥的多肽化合物 |
WO2023031455A1 (en) | 2021-09-06 | 2023-03-09 | Sanofi Sa | New peptides as potent and selective gip receptor agonists |
EP4259647A1 (en) * | 2021-09-15 | 2023-10-18 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
WO2023089594A1 (en) | 2021-11-22 | 2023-05-25 | Sun Pharmaceutical Industries Limited | Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof |
TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
WO2023193727A1 (zh) * | 2022-04-07 | 2023-10-12 | 广东众生睿创生物科技有限公司 | 多肽在制备治疗和/或预防糖尿病及肥胖症及其相关疾病药物中的制药用途 |
WO2024006662A1 (en) | 2022-06-30 | 2024-01-04 | Eli Lilly And Company | Tirzepatide compositions and use |
EP4299052A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and a permeation enhancer |
EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
TW202411244A (zh) * | 2022-07-13 | 2024-03-16 | 中國大陸商杭州中美華東製藥有限公司 | Glp-1/gip雙激動劑及其製備方法和用途 |
WO2024020388A1 (en) * | 2022-07-20 | 2024-01-25 | Viking Therapeutics, Inc. | Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders |
WO2024050289A1 (en) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | Compositions for oral delivery |
WO2024059674A1 (en) | 2022-09-15 | 2024-03-21 | Eli Lilly And Company | Gip and glp-1 dual agonist compounds |
WO2024061310A1 (zh) * | 2022-09-23 | 2024-03-28 | 博瑞生物医药(苏州)股份有限公司 | 一种glp-1和gip双受体激动剂药物组合物及其用途 |
WO2024077149A2 (en) | 2022-10-05 | 2024-04-11 | Eli Lilly And Company | Peptides for incretin synthesis |
CN117756913A (zh) * | 2022-11-07 | 2024-03-26 | 内蒙古博睿精创科技有限公司 | 一种新型长效多肽化合物、组合物及其应用 |
WO2024112617A2 (en) | 2022-11-21 | 2024-05-30 | Eli Lilly And Company | Process for preparing a gip/glp1 dual agonist |
CN116832141B (zh) * | 2023-06-06 | 2024-02-09 | 诺博泰科(成都)生物科技有限公司 | 一种用于治疗糖尿病的glp-1、gip和gcg受体三激动多肽化合物 |
CN116693652B (zh) * | 2023-08-02 | 2024-01-05 | 北京惠之衡生物科技有限公司 | 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050272652A1 (en) * | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
EP2292653B1 (en) * | 2005-02-02 | 2014-05-21 | Novo Nordisk A/S | Novel insulin derivatives |
US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
CA2732973A1 (en) * | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Glucose-dependent insulinotropic polypeptide analogues |
EP2340049B1 (en) | 2008-09-12 | 2015-11-11 | Novo Nordisk A/S | Method of acylating a peptide or protein |
CN101367873B (zh) * | 2008-10-08 | 2011-05-04 | 南开大学 | 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用 |
TWI489992B (zh) | 2008-12-19 | 2015-07-01 | 印地安那大學研究及技術公司 | 醯胺系胰高血糖素超級家族之胜肽前驅藥物 |
GB0917072D0 (en) * | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
EP2528618A4 (en) | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
KR101091041B1 (ko) * | 2010-07-29 | 2011-12-09 | 고려대학교 산학협력단 | 새로운 재조합 글루코스 의존성 인슐린분비 펩타이드(rcGIP) 작용제 및 그 용도 |
KR20140020851A (ko) * | 2010-12-22 | 2014-02-19 | 마르카디아 바이오테크, 인코퍼레이트 | Gip 및 glp-1 수용체-활성 글루카곤계 펩타이드를 이용한 대사장애 및 비만의 치료방법 |
SG191194A1 (en) | 2010-12-22 | 2013-07-31 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity |
EP2694095B1 (en) | 2011-04-05 | 2018-03-07 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
JP5914641B2 (ja) | 2011-06-10 | 2016-05-11 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドBeijing Hanmi Pharmaceutical Co., Ltd. | グルコース依存性インスリン分泌刺激ポリペプチドのアナログ、医薬組成物及びその使用 |
WO2012171994A1 (en) | 2011-06-15 | 2012-12-20 | Novo Nordisk A/S | Multi substituted insulins |
AU2012311484B2 (en) * | 2011-09-23 | 2017-04-13 | Novo Nordisk A/S | Novel glucagon analogues |
AP2014007797A0 (en) * | 2011-12-23 | 2014-07-31 | Boehringer Ingelheim Int | Glucagon analogues |
NZ702333A (en) | 2012-05-03 | 2017-06-30 | Zealand Pharma As | Gip-glp-1 dual agonist compounds and methods |
CN104583232B (zh) | 2012-06-21 | 2018-04-13 | 印第安纳大学研究及科技有限公司 | 展现gip受体活性的胰高血糖素类似物 |
EP2908845A1 (en) | 2012-10-17 | 2015-08-26 | Novo Nordisk Health Care AG | Fatty acid acylated amino acids for growth hormone delivery |
ES2653765T3 (es) | 2012-12-21 | 2018-02-08 | Sanofi | Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón |
EA035813B1 (ru) * | 2013-05-28 | 2020-08-14 | Такеда Фармасьютикал Компани Лимитед | Пептид-коагонист рецептора glp-1 и рецептора gip и его применение для профилактики или лечения ожирения или диабета у млекопитающего |
-
2015
- 2015-01-09 JO JOP/2020/0119A patent/JOP20200119A1/ar unknown
- 2015-12-22 JO JOP/2015/0334A patent/JO3575B1/ar active
- 2015-12-22 AR ARP150104252A patent/AR103242A1/es unknown
- 2015-12-22 TW TW104143220A patent/TWI582109B/zh active
-
2016
- 2016-01-05 ES ES16703620T patent/ES2747928T3/es active Active
- 2016-01-05 DK DK16703620.1T patent/DK3242887T3/da active
- 2016-01-05 PL PL16703620T patent/PL3242887T3/pl unknown
- 2016-01-05 CN CN201680005007.XA patent/CN107207576B/zh active Active
- 2016-01-05 MX MX2017008927A patent/MX2017008927A/es unknown
- 2016-01-05 CR CR20170310A patent/CR20170310A/es unknown
- 2016-01-05 MY MYPI2017702464A patent/MY193616A/en unknown
- 2016-01-05 RS RS20191110A patent/RS59146B1/sr unknown
- 2016-01-05 SI SI201630358T patent/SI3242887T1/sl unknown
- 2016-01-05 EP EP16703620.1A patent/EP3242887B1/en active Active
- 2016-01-05 ME MEP-2019-238A patent/ME03494B/me unknown
- 2016-01-05 WO PCT/US2016/012124 patent/WO2016111971A1/en active Application Filing
- 2016-01-05 TN TN2017000198A patent/TN2017000198A1/en unknown
- 2016-01-05 KR KR1020217037823A patent/KR20210145311A/ko not_active Application Discontinuation
- 2016-01-05 KR KR1020177018584A patent/KR101957620B1/ko active IP Right Grant
- 2016-01-05 KR KR1020237004037A patent/KR20230023822A/ko not_active Application Discontinuation
- 2016-01-05 HU HUE16703620A patent/HUE045860T2/hu unknown
- 2016-01-05 PT PT167036201T patent/PT3242887T/pt unknown
- 2016-01-05 AU AU2016205435A patent/AU2016205435B2/en active Active
- 2016-01-05 MD MDE20170269 patent/MD3242887T2/ro unknown
- 2016-01-05 CN CN202011598548.2A patent/CN112608377B/zh active Active
- 2016-01-05 MA MA050422A patent/MA50422A/fr unknown
- 2016-01-05 KR KR1020197006498A patent/KR102330764B1/ko active IP Right Grant
- 2016-01-05 SG SG11201705603YA patent/SG11201705603YA/en unknown
- 2016-01-05 EP EP19188718.1A patent/EP3597662A1/en active Pending
- 2016-01-05 MA MA41315A patent/MA41315B1/fr unknown
- 2016-01-05 EA EA202090392A patent/EA202090392A3/ru unknown
- 2016-01-05 EA EA201892057A patent/EA035055B1/ru unknown
- 2016-01-05 NZ NZ732000A patent/NZ732000A/en unknown
- 2016-01-05 JP JP2016549352A patent/JP6219534B2/ja active Active
- 2016-01-05 PE PE2017001142A patent/PE20170954A1/es unknown
- 2016-01-05 US US14/987,791 patent/US9474780B2/en active Active
- 2016-01-05 LT LT16703620T patent/LT3242887T/lt unknown
- 2016-01-05 CA CA2973352A patent/CA2973352C/en active Active
- 2016-01-05 EA EA201791281A patent/EA031591B1/ru unknown
- 2016-05-01 UA UAA201707109A patent/UA118239C2/uk unknown
-
2017
- 2017-05-24 IL IL252499A patent/IL252499B/en active IP Right Grant
- 2017-06-01 SV SV2017005453A patent/SV2017005453A/es unknown
- 2017-06-08 ZA ZA2017/03930A patent/ZA201703930B/en unknown
- 2017-06-22 DO DO2017000153A patent/DOP2017000153A/es unknown
- 2017-07-03 CL CL2017001760A patent/CL2017001760A1/es unknown
- 2017-07-05 MX MX2021005835A patent/MX2021005835A/es unknown
- 2017-07-05 CO CONC2017/0006737A patent/CO2017006737A2/es unknown
- 2017-07-07 PH PH12017501252A patent/PH12017501252A1/en unknown
- 2017-07-07 EC ECIEPI201743648A patent/ECSP17043648A/es unknown
- 2017-09-27 JP JP2017186721A patent/JP6545766B2/ja active Active
-
2019
- 2019-06-19 JP JP2019113638A patent/JP6754867B2/ja active Active
- 2019-09-05 HR HRP20191614 patent/HRP20191614T1/hr unknown
- 2019-09-12 CY CY20191100957T patent/CY1122028T1/el unknown
-
2020
- 2020-08-04 IL IL276492A patent/IL276492B/en active IP Right Grant
-
2021
- 2021-03-16 IL IL281545A patent/IL281545A/en unknown
-
2023
- 2023-01-31 LT LTPA2023504C patent/LTPA2023504I1/lt unknown
- 2023-01-31 HU HUS2300006C patent/HUS2300006I1/hu unknown
- 2023-01-31 FR FR23C1006C patent/FR23C1006I2/fr active Active
- 2023-02-02 NO NO2023005C patent/NO2023005I1/no unknown
- 2023-02-02 FI FIC20230005C patent/FIC20230005I1/fi unknown
- 2023-02-07 NL NL301217C patent/NL301217I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201791281A1 (ru) | Соединения-коагонисты гип и гпп-1 | |
MY197569A (en) | Gip/glp1 co-agonist compounds | |
PH12019501216A1 (en) | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists | |
EA201690660A1 (ru) | Соединения и способы на основе двойного агониста гип и гпп-1 | |
SA518391903B1 (ar) | معاضد مستقبل جلوكاجون/الببتيد 1 المشابه للجلوكاجون/البولي ببتيد المحب للأنسولين المعتمد على الجلوكوز الثلاثي | |
PH12020551742A1 (en) | Gip derivatives and uses thereof | |
MX2016013243A (es) | Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4. | |
MX2016013244A (es) | Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon. | |
PH12015500194A1 (en) | Fusion proteins for treating a metabolic syndrome | |
MX2016013248A (es) | Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4. | |
ECSP12012357A (es) | Análogos del glucagón | |
MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
MX2018000362A (es) | Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon. | |
JOP20220024A1 (ar) | مركبات مساعدة لـ gipr | |
MX2019006600A (es) | Agonistas duales de glp-1/glp-2. | |
EA201790254A1 (ru) | Новые модуляторы рецептора glp-1 | |
TR201900959T4 (tr) | Bi̇leşi̇mler ve bunlarin tibbi̇ kullanimi. | |
EA202092891A1 (ru) | Соединения-коагонисты gip/glp1 | |
AR107282A1 (es) | Agonista triple que tiene actividad para un receptor de glucagón, un receptor del péptido 1 similar al glucagón (glp-1) y un receptor de péptido insulinotrópico dependiente de glucosa (gip) |